Free Trial to Paid Conversion Benchmarks: An Audit, Not Another List

If someone tells you their free trial to paid conversion benchmarks, the first question is: from which study? Search for this number and you'll find it reported as 8.9%, 18.2%, and 24.8% in the same month, sometimes on the same listicle. None of these sources agree, one of them isn't traceable to a real dataset, and almost nobody citing them explains why the gap exists. Before you compare your trial against any of these numbers, you need to know what each one actually measured.

This isn't a listicle of round numbers. It's an audit of the three studies actually behind the benchmarks that get repeated everywhere, the one widely-cited figure that should be dropped entirely, and the full-funnel math that explains why a single conversion percentage, in isolation, tells you almost nothing about whether your trial is healthy.

Free Trial to Paid Conversion Benchmarks: Three Sources, Three Numbers

Most "benchmark" content on this topic is aggregated content citing other aggregated content, several layers removed from any underlying dataset. Strip that away and there are three studies with an actual sample and a stated methodology worth citing directly.

Each of these numbers is defensible within its own sample. None of them is a universal benchmark. First Page Sage's 86 clients skew toward a specific type of engagement (companies working with a growth agency, which already selects for a certain level of GTM sophistication). ChartMogul/ProductLed's 200 products are a broader, more general B2B sample, which is part of why its number sits meaningfully lower. GrowthSpree's range is wide because it's aggregating across mixed sources rather than running a single consistent methodology. Quoting any one of these as "the" free trial conversion rate, without naming which study and which trial type, is the root of most of the confusion in this space.

Why Opt-In vs Opt-Out Explains More Variance Than Industry

Look again at the table above. Within every single source, the gap between the opt-in and opt-out columns is larger than the gap between sources. That's the signal buried under all the "benchmarks by industry" content: your trial's card-collection design predicts your conversion rate better than your vertical does.

This makes intuitive sense once you separate the two funnels. An opt-out trial (card required upfront) has already filtered for purchase intent before a single trial user exists. Someone who hands over a card to try your product is a fundamentally different population than someone who signs up with an email address alone. Comparing an opt-in rate against an opt-out rate and calling the difference "industry variance" is comparing two different funnels, not two different markets.

According to ChartMogul/ProductLed's 2026 data, only about 20% of SaaS products with a free trial actually require a card at signup. That's a deliberate design choice most companies aren't making, and it's the single biggest lever behind the wide range of numbers floating around this topic, well ahead of company size, pricing tier, or industry vertical.

The Full-Funnel Math: Why the Isolated Ratio Misleads

Here's where most benchmark content stops short: it reports the conversion percentage and moves on, as if a higher percentage always means a better outcome. It doesn't, because the percentage is only half the funnel. The other half is how many signups you get in the first place, and the two move in opposite directions.

Per 1,000 website visitors, ChartMogul/ProductLed's data breaks down like this:

The opt-out trial converts at roughly 3-5x the rate of the opt-in trial, but the interesting number is on the right: 10.5 paying customers versus 3.6, from a smaller pool of signups. Requiring a card doesn't just improve the percentage, it improves the absolute output, because it filters out visitors who were never going to buy before they ever consume onboarding resources. This is exactly why an isolated conversion rate, without the signup volume next to it, is close to useless for a go/no-go decision on trial design.

The reverse is also true: a lower opt-in conversion rate paired with dramatically higher signup volume can still produce more net paying customers, depending on where your funnel bottleneck actually sits. There is no substitute for running this math on your own numbers.

Benchmarks by Trial Model: Standard, Freemium, Reverse Trial

Trial design isn't binary. GrowthSpree's 2026 aggregate data covers three distinct models, and they don't just differ in conversion rate, they differ in what they optimize for:

• Standard trial (time-limited, full or near-full access): 8-22% opt-in, median 14%; 35-55% opt-out, median 44%.
• Freemium (permanent free tier, no expiration): 2-8%, median 4.5%.
• Reverse trial (full access up front, steps down to a limited free tier at expiration): 18-32%, median 24%.

Freemium's low conversion rate isn't necessarily a failure mode. Freemium products generate roughly 2x more signups than a standard trial, according to GrowthSpree's data, which means the net paying customers per visitor across the whole funnel often ends up close to identical between freemium and standard trial. The model doesn't change your outcome as much as it changes where the friction sits: freemium trades a worse conversion percentage for a much larger top of funnel and a longer evaluation window, while a standard trial concentrates the decision into a fixed window.

Reverse trial sits in an interesting middle position: it gives users everything up front (removing the "what am I missing behind the paywall" hesitation that suppresses opt-in trial conversion) while still creating urgency once the downgrade hits. The 24% median is a meaningful step up from standard opt-in trials, without requiring a card at signup the way opt-out does.

The Figure to Discard: The "24.8%" That Isn't Real

If you've researched this topic before, you've likely seen a claim along the lines of "OpenView Partners and ChartMogul analyzed 3,200 companies and found a 24.8% average free trial conversion rate." It gets cited constantly, usually without a link to the original report, and it's the number most often used to make a middling conversion rate sound acceptable.

It should be dropped. OpenView Partners does not currently operate as an active publisher of this kind of research in the way the citation implies, and no version of this claim traces back to a locatable dataset, sample description, or methodology. Nobody citing "24.8%" can point to the underlying study, because as far as can be determined, it doesn't exist as described. This single fabricated-or-misattributed statistic, repeated across dozens of sites that cite each other instead of a primary source, is a large part of why "free trial conversion benchmark" content has such a bad reputation for accuracy. Treat any figure you can't trace to a named study, sample size, and methodology the same way: assume it's unverifiable until proven otherwise.

"Nobody citing the 24.8% figure can point to the underlying study, because as far as can be determined, it doesn't exist as described."

This is the audit's core finding, not a competitor's claim.

What to Measure Instead: Activation and Time-to-Value

Trial-to-paid conversion is a lagging indicator. By the time you can measure it, the outcome for that cohort is already decided. The two leading indicators that actually explain your conversion number, and that you can act on while a trial is still running, are activation rate and time-to-value (TTV).

Median B2B SaaS activation sits around 37.5%, based on Userpilot's study of 62 companies, meaning that for the typical SaaS product, roughly two out of three trial signups never reach the point where the product actually delivers value to them. Amplitude's 2025 study of 2,600+ companies found that more than 98% of new users churn within two weeks if they never hit a value milestone. Put those two numbers together and the conclusion is unavoidable: for most products, the conversion rate is being decided in the first days of the trial, at the activation step, long before anyone looks at the pricing page.

If you're benchmarking your trial-to-paid rate and it comes up short, the fix is rarely a pricing page tweak or a better paywall. It's almost always upstream, in whether new users are reaching activation fast enough to still be there when the trial ends. That diagnostic, what counts as a real activation event, how activation varies by segment and complexity, and where the day-3, day-7, and day-14 drop-off windows actually sit, is its own full analysis, and it's the natural next read once you've placed your trial-to-paid number in context.

Activation targets aren't one-size-fits-all either

The same trap that distorts trial-to-paid benchmarks shows up in activation benchmarks: a single median hides more than it reveals. Userpilot's data shows activation varying by as much as 10.9x between verticals: AI/ML products activate at a median of 54.8%, while FinTech and insurance sit around 5.0%, reflecting how much harder it is to reach "value" in a regulated, integration-heavy product. Segmenting by company size matters just as much: ProductQuant's 2026 targets put SMB activation at 35-50%, mid-market at 40-55%, and enterprise at 50-65%. Notably, companies in the $10M-$50M revenue band see activation fall to roughly 17.6%, a well-documented dip that happens because signup volume scales faster than onboarding infrastructure at that stage.

Time-to-activate follows the same logic. A simple product should activate a user in 1-3 days; a medium-complexity product in around 7 days; a genuinely complex, integration-heavy product can reasonably take 14-30 days. Time-to-value (TTV) benchmarked by deal size, per Perspective AI's 2026 data, tells a similar story: sub-$5K ARR accounts hit a value milestone in a median of 11 minutes, $5-25K ARR accounts take 2.4 days, $25-100K accounts take 9 days, and $100K+ accounts take 23 days. (Perspective AI's data is a vendor study with an evident commercial angle, so treat the absolute figures as directional rather than gospel, but the ordering, that TTV scales with deal complexity, is intuitive and consistent with the other sources here.)

The practical implication: if you're comparing your trial-to-paid number against a generic benchmark without first asking whether your activation window matches your product's actual complexity, you're very likely benchmarking against the wrong reference class. A complex, high-ACV product with a 14-day trial and a 14-30 day time-to-activate isn't underperforming, it's structurally mismatched, and the fix is trial length or a different activation milestone, not a lower price.

A Framework for Choosing Your Benchmark

Instead of asking "is my conversion rate good," ask these four questions in order:

1. What's my trial model? Standard, freemium, or reverse trial. Don't compare across models without adjusting for signup volume differences.
2. Do I require a card at signup? If yes, benchmark against the opt-out numbers (25-35% good, 50-60% excellent per ChartMogul/ProductLed). If no, benchmark against opt-in (4-6% good, 10-15% excellent).
3. What's my activation rate, and how fast do users reach it? If activation is below the ~37.5% median for your segment, or taking longer than your trial window allows, your conversion number will underperform regardless of pricing or paywall design. Fix this before touching anything downstream.
4. Am I citing a study I can actually name? If a benchmark doesn't come with a sample size, a year, and a named source, don't use it to make a decision about your own trial.

This is also the reason a single company-wide "conversion rate" is often the wrong unit of analysis. A B2B SaaS company selling into two segments with different deal sizes and different levels of product complexity should expect two different activation curves and two different conversion rates, and blending them into one headline number hides exactly the diagnostic information you need.

Why the Benchmark Should Connect Back to CAC

One more reason a single, isolated conversion percentage is the wrong metric to optimize in isolation: it says nothing about whether the customers you're converting are worth what you spent to get them. Median B2B SaaS customer acquisition cost in 2026 sits around $1,200 per customer. Run that against your own funnel math from earlier in this piece: at an 8% opt-in conversion rate producing 3.6 paying customers per 1,000 visitors, your effective acquisition cost is very different from a 30% opt-out rate producing 10.5 paying customers from the same visitor pool, once you account for what it costs to drive those 1,000 visitors in the first place.

This is why benchmark chasing, on its own, is a weak strategy. A team that pushes its opt-in conversion rate from 8% to 12% by adding friction that also cuts signup volume in half may have "improved" the headline metric while making net customer acquisition worse. The number that should actually drive decisions is paying customers acquired per dollar of CAC, with trial-to-paid conversion as one input among several, not the target itself.

The Bottom Line

The free trial to paid conversion benchmarks that circulate online contradict each other because they're measuring different funnels, different populations, and in at least one widely-cited case, a study that doesn't appear to exist. The fix isn't finding the "real" universal number, because there isn't one. It's identifying your trial model, requiring the same design (opt-in vs opt-out) in whatever you compare against, and treating the conversion percentage as the output of activation and time-to-value, not as the starting point for diagnosis.

We're running a small number of free onboarding pilots with SaaS teams who want real, session-level data on where their own trial users get stuck, rather than another industry-wide average. If that's useful to you, we'd like to talk.